Search results
Showing 46 to 60 of 158 results for urinary tract infection
Memokath-028, 044 and 045 stents for urethral obstruction (MIB123)
NICE has developed a medtech innovation briefing (MIB) on Memokath-028, 044 and 045 stents for urethral obstruction .
Axonics sacral neuromodulation system for treating refractory overactive bladder (HTG554)
Evidence-based recommendations on Axonics sacral neuromodulation system for treating refractory overactive bladder.
Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia (HTG545)
Evidence-based recommendations on Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Complicated intra-abdominal infections: ceftolozane/tazobactam (ESNM75)
Summary of the evidence on ceftolozane/tazobactam for treating complicated intra-abdominal infections to inform local NHS planning and decision-making
QuickChange Incontinence Wrap for urinary incontinence in men (MIB237)
NICE has developed a medtech innovation briefing (MIB) on QuickChange Incontinence Wrap for urinary incontinence in men .
Cryotherapy as a primary treatment for prostate cancer (HTG91)
Evidence-based recommendations on cryotherapy as a primary treatment for prostate cancer. This involves using cold temperature to freeze and destroy cancer tissue as a first treatment for cancer that hasn't spread far from the prostate.
View recommendations for HTG91Show all sections
Sections for HTG91
This guideline covers diagnosing and treating jaundice, which is caused by increased levels of bilirubin in the blood, in newborn babies (neonates). It aims to help detect or prevent very high levels of bilirubin, which can be harmful if not treated.
Focal therapy using cryoablation for localised prostate cancer (HTG284)
Evidence-based recommendations on focal therapy using cryoablation for localised stage prostate cancer. This involves using freezing (cryotherapy) needles to find and destroy only the cancerous part of the prostate.
View recommendations for HTG284Show all sections
Sections for HTG284
Surgery for stress urinary incontinence Patient decision aid ? 1 c NICE 2019. All rights reserved. Subject to Notice of rights. Last...
Empagliflozin in combination therapy for treating type 2 diabetes (TA336)
Evidence-based recommendations on empagliflozin (Jardiance) in combination therapy for treating type 2 diabetes.
Mirabegron for treating symptoms of overactive bladder (TA290)
Evidence-based recommendations on mirabegron (Betmiga) for treating overactive bladder in adults.
strategies to reduce the risk of symptomatic urinary tract infections:- In people with neurogenic lower urinary...
Neonatal infection: antibiotics for prevention and treatment (NG195)
This guideline covers preventing bacterial infection in healthy babies of up to and including 28 days corrected gestational age, treating pregnant women whose unborn baby is at risk of infection, and caring for babies of up to and including 28 days corrected gestational age with a suspected or confirmed bacterial infection. It aims to reduce delays in recognising and treating infection and prevent unnecessary use of antibiotics. The guideline does not cover viral infections.
This quality standard covers the assessment and early management of fever with no obvious cause in babies and children (from birth to 5 years). It describes high-quality care in priority areas for improvement.
Summary of the evidence on the antimicrobial prescribing of ceftolozane with tazobactam for hospital-acquired pneumonia, including ventilator-associated